Martin Reck, MD and Ph.D at the German Center of Lung Research, presented at this year's ASCO20 Virtual Scientific program the first results from the CheckMate 9LA trial – a randomized trial investigating the combination of a limited cause of chemotherapy together with nivolumab and ipilimumab as first line treatment for patients with advanced non small cell lung cancer. This trial has compared first-line therapy with nivolumab plus ipilimumab in combined two-cycle chemotherapy with 4-cycle chemo (control group) for patients with stage IV recurrent non-small cell lung cancer. The goal was to achieve rapid disease control with a continuous improvement of overall survival through PD-L1 and CTLA-4 inhibiters combined with chemotherapy. None of the patients had EGFR / ALK mutation. The patients in immunotherapy were treated until disease progression, unacceptable side effects or for two years. The study showed that first-line therapy with nivolumab plus ipilimumab in combination with chemotherapy significantly improved overall survival compared with chemotherapy alone (HR 0.69, 96.71% CI: 0.55–0.87; P = 0.0006). There was also seen statistically significant improvement in PFS and ORR corresponding to 15 months compared to 10.9 months in chemotherapy. First year’s OS rate was respectively 63 and 47%. Read the abstract published on Asco here.